Skip to content
value.today
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc.

Relay Therapeutics, Inc. is listed today as Relay Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Relay Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2024$30 MPrivate placement after listing$10 to $50 million

Relay Therapeutics, Inc.: Private sale, Jan 2024

Investors in this round

1 investor had bought by the notice of Jan 10, 2024: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Relay Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brian K. Adams · Executive Officer
  • Donald A. Bergstrom · Executive Officer
  • Peter A. Rahmer · Executive Officer
  • Sanjiv K. Patel · Executive Officer, Director
  • Thomas A. Catinazzo · Executive Officer
  • Alexis A. Borisy · Director
  • Douglas S. Ingram · Director
  • Jami S. Rubin · Director
  • Laura S. Shawver · Director
  • Linda A. Hill · Director
  • Mark S. Murcko · Director
  • Sekar S. Kathiresan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian Adams, Chief Legal Officer. Source: SEC Form D, newest notice filed Jan 10, 2024. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Relay Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2024).

    SEC Form D · Jan 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2024

That is all the official record says: Relay Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Relay Therapeutics, Inc. are on record.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Relay Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Alexandria Venture Investments, LLCVenture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Alexis BorisyPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2020)SEC Form 3
Mark MurckoPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2020)SEC Form 3
Picularium, LLCOthernot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
SB Investment Advisers (UK) LTDFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Softbank Vision Fund (aiv M2) L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
SVF Pauling (Cayman) LtdCompanynot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures GP III, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures GP IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures III, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Third Rock Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
TRV GP III, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Trv Gp Iv, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Relay Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Relay Therapeutics, Inc.
NameRoleNamed in
Brian K. AdamsExecutive officerJan 2024
Donald A. BergstromExecutive officerJan 2024
Peter A. RahmerExecutive officerJan 2024
Sanjiv K. PatelExecutive officerJan 2024
Thomas A. CatinazzoExecutive officerJan 2024
Alexis A. BorisyDirectorJan 2024
Douglas S. IngramDirectorJan 2024
Jami S. RubinDirectorJan 2024
Laura S. ShawverDirectorJan 2024
Linda A. HillDirectorJan 2024
Mark S. MurckoDirectorJan 2024
Sanjiv K. PatelDirectorJan 2024
Sekar S. KathiresanDirectorJan 2024

About

Company in Cambridge, United States.

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.